Targeting the NF-κB activation pathway, commonly activated in breast cancer cells, is expected to lower the survival threshold even if NF-κB inhibition is generally insufficient for inducing pronounced apoptosis in cancer cells. The gene discussed is NFKB1; the disease is breast carcinoma.